{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:16:49Z","timestamp":1789730209339,"version":"4.0.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metab"],"DOI":"10.1186\/s40170-025-00402-5","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T17:19:37Z","timestamp":1753463977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacological inhibition of Peroxisome Proliferation-Activated Receptor Delta (PPAR\u03b4) imparts selective leukemia cell death"],"prefix":"10.1186","volume":"13","author":[{"given":"Yingying","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Parfenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolina","family":"Vrdoljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Luc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Doxey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"14","key":"402_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","volume":"341","author":"B L\u00f6wenberg","year":"1999","unstructured":"L\u00f6wenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051\u201362. https:\/\/doi.org\/10.1056\/NEJM199909303411407.","journal-title":"N Engl J Med"},{"issue":"23","key":"402_CR2","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O\u2019Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, D\u00f6hner K, Schlenk RF, D\u00f6hner H, Campbell PJ. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1516192.","journal-title":"N Engl J Med"},{"issue":"3","key":"402_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502\u201326. https:\/\/doi.org\/10.1002\/ajh.26822.","journal-title":"Am J Hematol"},{"key":"402_CR4","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute; 2024 Apr 17. [updated: 2024 Nov 5; cited 2024 Nov 19]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Data source(s): SEER Incidence Data, November 2023 Submission (1975\u20132021), SEER 22 registries."},{"issue":"8","key":"402_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/cells8080805","volume":"8","author":"J Kreitz","year":"2019","unstructured":"Kreitz J, Sch\u00f6nfeld C, Seibert M, Stolp V, Alshamleh I, Oellerich T, Steffen B, Schwalbe H, Schn\u00fctgen F, Kurrle N, Serve H. Metabolic plasticity of acute myeloid leukemia. Cells. 2019;8(8):805. https:\/\/doi.org\/10.3390\/cells8080805.","journal-title":"Cells"},{"issue":"375","key":"402_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2026","volume":"6","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;6(375): n2026. https:\/\/doi.org\/10.1136\/bmj.n2026.","journal-title":"BMJ"},{"issue":"9","key":"402_CR7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/cells8090967","volume":"8","author":"I Castro","year":"2019","unstructured":"Castro I, Sampaio-Marques B, Ludovico P. Targeting metabolic reprogramming in acute myeloid leukemia. Cells. 2019;8(9):967. https:\/\/doi.org\/10.3390\/cells8090967.","journal-title":"Cells"},{"issue":"12","key":"402_CR8","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1080\/03007995.2021.1978960","volume":"37","author":"KJ Hatfield","year":"2021","unstructured":"Hatfield KJ, Gr\u00f8nningsaeter IS, Reikvam H. Future perspective: metabolism as a therapeutic target in acute myeloid leukemia - from Warburg to precision medicine. Curr Med Res Opin. 2021;37(12):2107\u201311. https:\/\/doi.org\/10.1080\/03007995.2021.1978960.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"402_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153\u201361. https:\/\/doi.org\/10.1016\/j.cmet.2013.05.017. Epub 2013 Jun 20. PMID: 23791484; PMCID: PMC3742569.","journal-title":"Cell Metab"},{"issue":"11","key":"402_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrc.2016.89","volume":"16","author":"F R\u00f6hrig","year":"2016","unstructured":"R\u00f6hrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16(11):732\u201349. https:\/\/doi.org\/10.1038\/nrc.2016.89. Epub 2016 Sep 23 PMID: 27658529.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"402_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbacli.2017.03.002.PMID:28331812;PMCID:PMC5357680","volume":"8","author":"T Pabst","year":"2017","unstructured":"Pabst T, Kortz L, Fiedler GM, Ceglarek U, Idle JR, Beyo\u011flu D. The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA Clin. 2017;8(7):105\u201314. https:\/\/doi.org\/10.1016\/j.bbacli.2017.03.002.PMID:28331812;PMCID:PMC5357680.","journal-title":"BBA Clin"},{"key":"402_CR12","doi-asserted-by":"publisher","unstructured":"Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, D\u00e1vila-Gonz\u00e1lez D, Wang K, S\u00e1nchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, G\u00f3mez H, Chang JC, Sanders ME, Cook RS, Arteaga CL. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Sci Transl Med. 2016 Apr 13;8(334):334ra53. https:\/\/doi.org\/10.1126\/scitranslmed.aad3001. Erratum in: Sci Transl Med. 2019 Jan 23;11(476):eaaw6162. https:\/\/doi.org\/10.1126\/scitranslmed.aaw6162.","DOI":"10.1126\/scitranslmed.aad3001"},{"issue":"9","key":"402_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3389\/fgene.2018.00405","volume":"24","author":"M Maher","year":"2018","unstructured":"Maher M, Diesch J, Casquero R, Buschbeck M. Epigenetic-transcriptional regulation of fatty acid metabolism and its alterations in leukaemia. Front Genet. 2018;24(9):405. https:\/\/doi.org\/10.3389\/fgene.2018.00405. PMID:30319689;PMCID:PMC6165860.","journal-title":"Front Genet"},{"issue":"1","key":"402_CR14","doi-asserted-by":"publisher","first-page":"113112","DOI":"10.1016\/j.yexcr.2022.113112","volume":"415","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Guo H, Zhang Z, Lu W, Zhu J, Shi J. IL-6 promotes chemoresistance via upregulating CD36 mediated fatty acids uptake in acute myeloid leukemia. Exp Cell Res. 2022;415(1):113112. https:\/\/doi.org\/10.1016\/j.yexcr.2022.113112.","journal-title":"Exp Cell Res"},{"issue":"1","key":"402_CR15","doi-asserted-by":"publisher","first-page":"9104","DOI":"10.1038\/s41598-024-58689-1","volume":"14","author":"H \u00c5backa","year":"2024","unstructured":"\u00c5backa H, Masoni S, Poli G, Huang P, Gusso F, Granchi C, Minutolo F, Tuccinardi T, Hagstr\u00f6m-Andersson AK, Lindkvist-Petersson K. SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia. Sci Rep. 2024;14(1):9104. https:\/\/doi.org\/10.1038\/s41598-024-58689-1.","journal-title":"Sci Rep"},{"issue":"16","key":"402_CR16","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1182\/blood-2014-12-617498","volume":"126","author":"MR Ricciardi","year":"2015","unstructured":"Ricciardi MR, Mirabilii S, Allegretti M, Licchetta R, Calarco A, Torrisi MR, Fo\u00e0 R, Nicolai R, Peluso G, Tafuri A. Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. Blood. 2015;126(16):1925\u20139. https:\/\/doi.org\/10.1182\/blood-2014-12-617498.","journal-title":"Blood"},{"issue":"12","key":"402_CR17","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1158\/0008-5472.CAN-14-2676","volume":"75","author":"EA Lee","year":"2015","unstructured":"Lee EA, Angka L, Rota SG, Hanlon T, Mitchell A, Hurren R, Wang XM, Gronda M, Boyaci E, Bojko B, Minden M, Sriskanthadevan S, Datti A, Wrana JL, Edginton A, Pawliszyn J, Joseph JW, Quadrilatero J, Schimmer AD, Spagnuolo PA. Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death. Cancer Res. 2015;75(12):2478\u201388. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2676.","journal-title":"Cancer Res"},{"issue":"25","key":"402_CR18","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1182\/blood.2020008551","volume":"137","author":"M Tcheng","year":"2021","unstructured":"Tcheng M, Roma A, Ahmed N, Smith RW, Jayanth P, Minden MD, Schimmer AD, Hess DA, Hope K, Rea KA, Akhtar TA, Bohrnsen E, D\u2019Alessandro A, Mohsen AW, Vockley J, Spagnuolo PA. Very long chain fatty acid metabolism is required in acute myeloid leukemia. Blood. 2021;137(25):3518\u201332. https:\/\/doi.org\/10.1182\/blood.2020008551.","journal-title":"Blood"},{"key":"402_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","volume":"53","author":"J Berger","year":"2002","unstructured":"Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409\u201335. https:\/\/doi.org\/10.1146\/annurev.med.53.082901.104018. PMID: 11818483.","journal-title":"Annu Rev Med"},{"issue":"1","key":"402_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-5926-2-3.PMID:12622871;PMCID:PMC151270","volume":"2","author":"E Boitier","year":"2003","unstructured":"Boitier E, Gautier JC, Roberts R. Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp Hepatol. 2003;2(1):3. https:\/\/doi.org\/10.1186\/1476-5926-2-3.PMID:12622871;PMCID:PMC151270.","journal-title":"Comp Hepatol"},{"issue":"3","key":"402_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1172\/JCI27989.PMID:16511589;PMCID:PMC1386122","volume":"116","author":"P Lefebvre","year":"2006","unstructured":"Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116(3):571\u201380. https:\/\/doi.org\/10.1172\/JCI27989.PMID:16511589;PMCID:PMC1386122.","journal-title":"J Clin Invest"},{"issue":"6","key":"402_CR22","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1210\/endo.139.6.6049","volume":"139","author":"O Braissant","year":"1998","unstructured":"Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology. 1998;139(6):2748\u201354.","journal-title":"Endocrinology"},{"issue":"15","key":"402_CR23","doi-asserted-by":"publisher","first-page":"7355","DOI":"10.1073\/pnas.91.15.7355","volume":"91","author":"SA Kliewer","year":"1994","unstructured":"Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994;91(15):7355\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"402_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endo.137.1.8536636","volume":"137","author":"O Braissant","year":"1996","unstructured":"Braissant O, Foufelle F, Scotto C, Dau\u00e7a M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137(1):354\u201366. https:\/\/doi.org\/10.1210\/endo.137.1.8536636. PMID: 8536636.","journal-title":"Endocrinology"},{"issue":"5","key":"402_CR25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1161\/01.RES.0000060700.55247.7C","volume":"92","author":"AJ Gilde","year":"2003","unstructured":"Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta\/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res. 2003;92(5):518\u201324. https:\/\/doi.org\/10.1161\/01.RES.0000060700.55247.7C. Epub 2003 Feb 6 PMID: 12600885.","journal-title":"Circ Res"},{"issue":"3","key":"402_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.pharmthera.2009.12.001","volume":"125","author":"KD Wagner","year":"2010","unstructured":"Wagner KD, Wagner N. Peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther. 2010;125(3):423\u201335. https:\/\/doi.org\/10.1016\/j.pharmthera.2009.12.001. Epub 2009 Dec 22 PMID: 20026355.","journal-title":"Pharmacol Ther"},{"issue":"1\u20132","key":"402_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/13543776.2024.2332661","volume":"34","author":"B De Filippis","year":"2024","unstructured":"De Filippis B, Granese A, Ammazzalorso A. Peroxisome proliferator-activated receptor agonists and antagonists: an updated patent review (2020\u20132023). Expert Opin Ther Pat. 2024;34(1\u20132):83\u201398. https:\/\/doi.org\/10.1080\/13543776.2024.2332661. Epub 2024 Mar 20. PMID: 38501260.","journal-title":"Expert Opin Ther Pat"},{"issue":"8","key":"402_CR28","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/biom13081264","volume":"13","author":"S Kamata","year":"2023","unstructured":"Kamata S, Honda A, Ishii I. Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease. Biomolecules. 2023;13(8):1264. https:\/\/doi.org\/10.3390\/biom13081264.","journal-title":"Biomolecules"},{"issue":"11","key":"402_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.599995","volume":"23","author":"Y Tan","year":"2021","unstructured":"Tan Y, Wang M, Yang K, Chi T, Liao Z, Wei P. PPAR-\u03b1 modulators as current and potential cancer treatments. Front Oncol. 2021;23(11): 599995. https:\/\/doi.org\/10.3389\/fonc.2021.599995.","journal-title":"Front Oncol"},{"issue":"22","key":"402_CR30","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.3390\/nu15224772","volume":"15","author":"P Hu","year":"2023","unstructured":"Hu P, Li K, Peng X, Kan Y, Li H, Zhu Y, Wang Z, Li Z, Liu HY, Cai D. Nuclear receptor PPAR\u03b1 as a therapeutic target in diseases associated with lipid metabolism disorders. Nutrients. 2023;15(22):4772. https:\/\/doi.org\/10.3390\/nu15224772.","journal-title":"Nutrients"},{"issue":"1","key":"402_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tips.2023.11.004","volume":"45","author":"C Titus","year":"2024","unstructured":"Titus C, Hoque MT, Bendayan R. PPAR agonists for the treatment of neuroinflammatory diseases. Trends Pharmacol Sci. 2024;45(1):9\u201323. https:\/\/doi.org\/10.1016\/j.tips.2023.11.004.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"402_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.44","volume":"4","author":"A Karabatsiakis","year":"2014","unstructured":"Karabatsiakis A, B\u00f6ck C, Salinas-Manrique J, Kolassa S, Calzia E, Dietrich DE, Kolassa IT. Mitochondrial respiration in peripheral blood mononuclear cells correlates with depressive subsymptoms and severity of major depression. Transl Psychiatry. 2014;4(6): e397. https:\/\/doi.org\/10.1038\/tp.2014.44.","journal-title":"Transl Psychiatry"},{"issue":"11","key":"402_CR33","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-17-0292","volume":"16","author":"SG Rota","year":"2017","unstructured":"Rota SG, Roma A, Dude I, Ma C, Stevens R, MacEachern J, Graczyk J, Espiritu SMG, Rao PN, Minden MD, Kreinin E, Hess DA, Doxey AC, Spagnuolo PA. Estrogen receptor \u03b2 is a novel target in acute myeloid leukemia. Mol Cancer Ther. 2017;16(11):2618\u201326. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0292. Epub 2017 Aug 23 PMID: 28835383.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"402_CR34","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1080\/10428194.2016.1218005","volume":"58","author":"M Tcheng","year":"2017","unstructured":"Tcheng M, Samudio I, Lee EA, Minden MD, Spagnuolo PA. The mitochondria target drug avocatin B synergizes with induction chemotherapeutics to induce leukemia cell death. Leuk Lymphoma. 2017;58(4):986\u20138. https:\/\/doi.org\/10.1080\/10428194.2016.1218005.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"402_CR35","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, F\u00e9liu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais JC, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, R\u00e9cher C, Sarry JE. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7(7):716\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0441.","journal-title":"Cancer Discov"},{"issue":"7","key":"402_CR36","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/0006-2952(93)90465-9","volume":"46","author":"FN Ko","year":"1993","unstructured":"Ko FN, Hsiao G, Chen IS, Wu SJ, Teng CM. Inhibition of collagen-induced platelet aggregation and adhesion by a pseudocyanide derivative of avicine isolated from Zanthoxylum integrifoliolum Merr. Biochem Pharmacol. 1993;46(7):1165\u201373. https:\/\/doi.org\/10.1016\/0006-2952(93)90465-9.","journal-title":"Biochem Pharmacol"},{"key":"402_CR37","doi-asserted-by":"publisher","unstructured":"Ma N, Shangguan F, Zhou H, Huang H, Lei J, An J, Jin G, Zhuang W, Zhou S, Wu S, Xia H, Yang H, Lan L. 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1\/Caspase-dependent cell death in pancreatic cancer cells through the disruption of oxaloacetic acid metabolism and accumulation of reactive oxygen species. Phytomedicine. 2022;102:154164. https:\/\/doi.org\/10.1016\/j.phymed.2022.154164.","DOI":"10.1016\/j.phymed.2022.154164"},{"issue":"14","key":"402_CR38","doi-asserted-by":"publisher","first-page":"1093650","DOI":"10.3389\/fphar.2023.1093650.PMID:37214469;PMCID:PMC10196025","volume":"5","author":"H Zhang","year":"2023","unstructured":"Zhang H, Shangguan F, Zhang L, Ma N, Song S, Ma L, Liu C, Liu M, An J, Li H, Cao Q. A novel mechanism of 6-methoxydihydroavicine in suppressing ovarian carcinoma by disrupting mitochondrial homeostasis and triggering ROS\/ MAPK mediated apoptosis. Front Pharmacol. 2023;5(14):1093650. https:\/\/doi.org\/10.3389\/fphar.2023.1093650.PMID:37214469;PMCID:PMC10196025.","journal-title":"Front Pharmacol"},{"key":"402_CR39","doi-asserted-by":"publisher","unstructured":"Alessia Roma, Matthew Tcheng, Nawaz Ahmed, Sarah Walker, Preethi Jayanth, Mark D. Minden, Kristin Hope, Praveen P. Nekkar Rao, Jessica Luc, Andrew C. Doxey, Julie A. Reisz, Rachel Culp-Hill, Angelo D'Alessandro, Paul A. Spagnuolo; Glutamine Metabolism Mediates Sensitivity to Respiratory Complex II Inhibition in Acute Myeloid Leukemia. Mol Cancer Res. 2022;20 (11): 1659\u20131673. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-1032.","DOI":"10.1158\/1541-7786.MCR-21-1032"},{"issue":"3","key":"402_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1097-2765(00)80467-0","volume":"3","author":"HE Xu","year":"1999","unstructured":"Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 1999;3(3):397\u2013403.","journal-title":"Mol Cell"},{"key":"402_CR41","doi-asserted-by":"publisher","first-page":"13416","DOI":"10.18632\/oncotarget.3826","volume":"6","author":"T Schumann","year":"2015","unstructured":"Schumann T, Adhikary T, Wortmann A, Finkernagel F, Lieber S, Schnitzer E, Legrand N, Schober Y, Nockher W, Toth PM, Diederich WE, Nist A, Stiewe T, et al. Deregulation of PPAR\u03b2\/\u03b4 target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. Oncotarget. 2015;6:13416\u201333.","journal-title":"Oncotarget"},{"issue":"12","key":"402_CR42","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1101\/gad.13.12.1561","volume":"13","author":"H Lim","year":"1999","unstructured":"Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM, Dey SK. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev. 1999;13(12):1561\u201374. https:\/\/doi.org\/10.1101\/gad.13.12.1561.","journal-title":"Genes Dev"},{"issue":"24","key":"402_CR43","doi-asserted-by":"publisher","first-page":"13275","DOI":"10.1073\/pnas.97.24.13275","volume":"97","author":"RA Gupta","year":"2000","unstructured":"Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A. 2000;97(24):13275\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"49","key":"402_CR44","doi-asserted-by":"publisher","first-page":"46260","DOI":"10.1074\/jbc.M107180200","volume":"276","author":"T Hatae","year":"2001","unstructured":"Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T. Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem. 2001;276(49):46260\u20137.","journal-title":"J Biol Chem"},{"issue":"2","key":"402_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/s0092-8674(03)00269-1","volume":"113","author":"YX Wang","year":"2003","unstructured":"Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 2003;113(2):159\u201370. https:\/\/doi.org\/10.1016\/s0092-8674(03)00269-1.","journal-title":"Cell"},{"key":"402_CR46","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/nm1116","volume":"10","author":"L Cheng","year":"2004","unstructured":"Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-\u03b4 deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med. 2004;10:1245\u201350. https:\/\/doi.org\/10.1038\/nm1116.","journal-title":"Nat Med"},{"issue":"5644","key":"402_CR47","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1126\/science.1087344","volume":"302","author":"CH Lee","year":"2003","unstructured":"Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science. 2003;302(5644):453\u20137. https:\/\/doi.org\/10.1126\/science.1087344. Epub 2003 Sep 11. Erratum in: Science. 2003 Nov 14;302(5648):1153.","journal-title":"Science"},{"issue":"7","key":"402_CR48","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1073\/pnas.0510815103","volume":"103","author":"CH Lee","year":"2006","unstructured":"Lee CH, Kang K, Mehl IR, Nofsinger R, Alaynick WA, Chong LW, Rosenfeld JM, Evans RM. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proc Natl Acad Sci U S A. 2006;103(7):2434\u20139. https:\/\/doi.org\/10.1073\/pnas.0510815103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"402_CR49","doi-asserted-by":"publisher","first-page":"13108","DOI":"10.1074\/jbc.M708086200","volume":"283","author":"VA Drover","year":"2008","unstructured":"Drover VA, Nguyen DV, Bastie CC, Darlington YF, Abumrad NA, Pessin JE, London E, Sahoo D, Phillips MC. CD36 mediates both cellular uptake of very long chain fatty acids and their intestinal absorption in mice. J Biol Chem. 2008;283(19):13108\u201315. https:\/\/doi.org\/10.1074\/jbc.M708086200.","journal-title":"J Biol Chem"},{"issue":"6","key":"402_CR50","doi-asserted-by":"publisher","first-page":"e20211314","DOI":"10.1084\/jem.20211314","volume":"219","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zhang J, Cui W, Silverstein RL. CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate. J Exp Med. 2022;219(6):e20211314. https:\/\/doi.org\/10.1084\/jem.20211314. Epub 2022 Apr 19. PMID: 35438721; PMCID: PMC9022290.","journal-title":"J Exp Med"},{"issue":"12","key":"402_CR51","first-page":"2853","volume":"41","author":"CL Hoppel","year":"1982","unstructured":"Hoppel CL. Carnitine and carnitine palmitoyltransferase in fatty acid oxidation and ketosis. Fed Proc. 1982;41(12):2853\u20137 PMID: 7128831.","journal-title":"Fed Proc"},{"issue":"5\u20136","key":"402_CR52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.mam.2004.06.004","volume":"25","author":"JP Bonnefont","year":"2004","unstructured":"Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25(5\u20136):495\u2013520. https:\/\/doi.org\/10.1016\/j.mam.2004.06.004. PMID: 15363638.","journal-title":"Mol Aspects Med"},{"issue":"5","key":"402_CR53","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10545-010-9061-2","volume":"33","author":"SM Houten","year":"2010","unstructured":"Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid \u03b2-oxidation. J Inherit Metab Dis. 2010;33(5):469\u201377. https:\/\/doi.org\/10.1007\/s10545-010-9061-2.","journal-title":"J Inherit Metab Dis"},{"key":"402_CR54","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.3390\/molecules24142545","volume":"24","author":"F Hong","year":"2019","unstructured":"Hong F, Pan S, Guo Y, Xu P, Zhai Y. PPARs as nuclear receptors for nutrient and energy metabolism. Molecules. 2019;24:2545. https:\/\/doi.org\/10.3390\/molecules24142545.","journal-title":"Molecules"},{"key":"402_CR55","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.3390\/ijms20205055","volume":"20","author":"HS Cheng","year":"2019","unstructured":"Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and development of PPAR modulators in health and disease: an update of clinical evidence. Int J Mol Sci. 2019;20:5055. https:\/\/doi.org\/10.3390\/ijms20205055.","journal-title":"Int J Mol Sci"},{"key":"402_CR56","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3390\/ijms19082189","volume":"19","author":"F Hong","year":"2018","unstructured":"Hong F, Xu P, Zhai Y. The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development. Int J Mol Sci. 2018;19:2189. https:\/\/doi.org\/10.3390\/ijms19082189.","journal-title":"Int J Mol Sci"},{"issue":"166","key":"402_CR57","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","volume":"15","author":"AZ Mirza","year":"2019","unstructured":"Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Eur J Med Chem. 2019;15(166):502\u201313. https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.067.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"402_CR58","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jacl.2015.03.011","volume":"9","author":"A Othman","year":"2015","unstructured":"Othman A, Benghozi R, Alecu I, Wei Y, Niesor E, von Eckardstein A, Hornemann T. Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: a novel approach for treating diabetic neuropathy? J Clin Lipidol. 2015;9(4):568\u201375. https:\/\/doi.org\/10.1016\/j.jacl.2015.03.011.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"402_CR59","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/vhrm.s6714","volume":"25","author":"P Alagona Jr","year":"2010","unstructured":"Alagona P Jr. Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vasc Health Risk Manag. 2010;25(6):351\u201362. https:\/\/doi.org\/10.2147\/vhrm.s6714.","journal-title":"Vasc Health Risk Manag"},{"key":"402_CR60","unstructured":"Eggleton JS, Jialal I. Thiazolidinediones. [Updated 2023 Feb 20]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551656\/"},{"key":"402_CR61","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1016\/j.atherosclerosis.2016.07.068","volume":"252","author":"D Gaudet","year":"2016","unstructured":"Gaudet D, Saheb S, Bruckert E, deGraaf J, Langslet G, Tardif JC, Bergheanu S, Steinberg A, Choi YJ, Martin R, et al. A pilot study of MBX-8025 in the treatment of homozygous familial hypercholesterolemia (HoFH). Atherosclerosis. 2016;252:e253.","journal-title":"Atherosclerosis"},{"key":"402_CR62","doi-asserted-by":"publisher","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladr\u00f3n de Guevara Cetina AL, Janczewska E, Zigmond E, Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londo\u00f1o Hurtado MC, Bergheanu S, Yang K, Choi YJ, Crittenden DB, McWherter CA; RESPONSE Study Group. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783\u2013794. https:\/\/doi.org\/10.1056\/NEJMoa2312100.","DOI":"10.1056\/NEJMoa2312100"},{"issue":"10","key":"402_CR63","doi-asserted-by":"publisher","first-page":"E1568","DOI":"10.1210\/jc.2011-1131","volume":"96","author":"EM Ooi","year":"2011","unstructured":"Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab. 2011;96(10):E1568\u201376. https:\/\/doi.org\/10.1210\/jc.2011-1131.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"402_CR64","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1172\/JCI38942","volume":"120","author":"I Samudio","year":"2010","unstructured":"Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010;120(1):142\u201356. https:\/\/doi.org\/10.1172\/JCI38942.","journal-title":"J Clin Invest"},{"key":"402_CR65","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1182\/blood-2019-125773","volume":"134","author":"CL Jones","year":"2019","unstructured":"Jones CL, Stevens BM, Culp-Hill R, et al. Inhibition of fatty acid metabolism re-sensitizes resistant leukemia stem cells to venetoclax with azacitidine[J]. Blood. 2019;134:1272.","journal-title":"Blood"},{"issue":"1","key":"402_CR66","doi-asserted-by":"publisher","first-page":"9104","DOI":"10.1038\/s41598-024-58689-1","volume":"14","author":"H \u00c5backa","year":"2024","unstructured":"\u00c5backa H, Masoni S, Poli G, Huang P, Gusso F, Granchi C, Minutolo F, Tuccinardi T, Hagstr\u00f6m-Andersson AK, Lindkvist-Petersson K. SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia. Sci Rep. 2024;14(1):9104. https:\/\/doi.org\/10.1038\/s41598-024-58689-1.","journal-title":"Sci Rep"},{"issue":"16","key":"402_CR67","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1182\/blood-2014-12-617498","volume":"126","author":"MR Ricciardi","year":"2015","unstructured":"Ricciardi MR, Mirabilii S, Allegretti M, Licchetta R, Calarco A, Torrisi MR, Fo\u00e0 R, Nicolai R, Peluso G, Tafuri A. Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. Blood. 2015;126(16):1925\u20139. https:\/\/doi.org\/10.1182\/blood-2014-12-617498.","journal-title":"Blood"},{"issue":"1","key":"402_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","volume":"19","author":"H Ye","year":"2016","unstructured":"Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, Jordan CT. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19(1):23\u201337. https:\/\/doi.org\/10.1016\/j.stem.2016.06.001.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"402_CR69","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12957-024-03581-5","volume":"22","author":"AK Abdel-Aziz","year":"2024","unstructured":"Abdel-Aziz AK. OXPHOS mediators in acute myeloid leukemia patients: prognostic biomarkers and therapeutic targets for personalized medicine. World J Surg Oncol. 2024;22(1):298. https:\/\/doi.org\/10.1186\/s12957-024-03581-5.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"402_CR70","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12967-021-02848-9","volume":"19","author":"S Mao","year":"2021","unstructured":"Mao S, Ling Q, Pan J, Li F, Huang S, Ye W, Wei W, Lin X, Qian Y, Wang Y, Huang X, Huang J, Wang J, Jin J. Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199. J Transl Med. 2021;19(1):181. https:\/\/doi.org\/10.1186\/s12967-021-02848-9.","journal-title":"J Transl Med"},{"issue":"4","key":"402_CR71","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13(4):227\u201332. https:\/\/doi.org\/10.1038\/nrg3185.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"402_CR72","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12864-017-3683-9","volume":"18","author":"K Perl","year":"2017","unstructured":"Perl K, Ushakov K, Pozniak Y, Yizhar-Barnea O, Bhonker Y, Shivatzki S, Geiger T, Avraham KB, Shamir R. Reduced changes in protein compared to mRNA levels across non-proliferating tissues. BMC Genomics. 2017;18(1):305. https:\/\/doi.org\/10.1186\/s12864-017-3683-9.","journal-title":"BMC Genomics"},{"key":"402_CR73","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.plantsci.2014.05.004","volume":"225","author":"L Pizarro","year":"2014","unstructured":"Pizarro L, Norambuena L. Regulation of protein trafficking: posttranslational mechanisms and the unexplored transcriptional control. Plant Sci. 2014;225:24\u201333. https:\/\/doi.org\/10.1016\/j.plantsci.2014.05.004.","journal-title":"Plant Sci"},{"issue":"10","key":"402_CR74","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1210\/endo.142.10.8446","volume":"142","author":"C Son","year":"2001","unstructured":"Son C, Hosoda K, Matsuda J, Fujikura J, Yonemitsu S, Iwakura H, Masuzaki H, Ogawa Y, Hayashi T, Itoh H, Nishimura H, Inoue G, Yoshimasa Y, Yamori Y, Nakao K. Up-regulation of uncoupling protein 3 gene expression by fatty acids and agonists for PPARs in L6 myotubes. Endocrinology. 2001;142(10):4189\u201394. https:\/\/doi.org\/10.1210\/endo.142.10.8446.","journal-title":"Endocrinology"},{"issue":"1","key":"402_CR75","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.febslet.2007.11.040","volume":"582","author":"SM Reilly","year":"2008","unstructured":"Reilly SM, Lee CH. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett. 2008;582(1):26\u201331. https:\/\/doi.org\/10.1016\/j.febslet.2007.11.040.","journal-title":"FEBS Lett"},{"issue":"12","key":"402_CR76","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1210\/me.2003-0151","volume":"17","author":"U Dressel","year":"2003","unstructured":"Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE. The peroxisome proliferator-activated receptor beta\/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol. 2003;17(12):2477\u201393. https:\/\/doi.org\/10.1210\/me.2003-0151.","journal-title":"Mol Endocrinol"},{"issue":"6\u20137","key":"402_CR77","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.bbabio.2010.02.035","volume":"1797","author":"V Azzu","year":"2010","unstructured":"Azzu V, Jastroch M, Divakaruni AS, Brand MD. The regulation and turnover of mitochondrial uncoupling proteins. Biochim Biophys Acta. 2010;1797(6\u20137):785\u201391. https:\/\/doi.org\/10.1016\/j.bbabio.2010.02.035.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"402_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178995","volume":"12","author":"R Florio","year":"2017","unstructured":"Florio R, De Lellis L, di Giacomo V, Di Marcantonio MC, Cristiano L, Basile M, Verginelli F, Verzilli D, Ammazzalorso A, Prasad SC, Cataldi A, Sanna M, Cimini A, Mariani-Costantini R, Mincione G, Cama A. Effects of PPAR\u03b1 inhibition in head and neck paraganglioma cells. PLoS One. 2017;12(6): e0178995. https:\/\/doi.org\/10.1371\/journal.pone.0178995.","journal-title":"PLoS One"},{"issue":"1","key":"402_CR79","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jnutbio.2012.06.005","volume":"24","author":"NW Chang","year":"2013","unstructured":"Chang NW, Wu CT, Chen DR, Yeh CY, Lin C. High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation. J Nutr Biochem. 2013;24(1):274\u201381. https:\/\/doi.org\/10.1016\/j.jnutbio.2012.06.005.","journal-title":"J Nutr Biochem"},{"issue":"13","key":"402_CR80","doi-asserted-by":"publisher","first-page":"15577","DOI":"10.18632\/oncotarget.6402","volume":"7","author":"K Chandran","year":"2016","unstructured":"Chandran K, Goswami S, Sharma-Walia N. Implications of a peroxisome proliferator-activated receptor alpha (PPAR\u03b1) ligand clofibrate in breast cancer. Oncotarget. 2016;7(13):15577\u201399. https:\/\/doi.org\/10.18632\/oncotarget.6402.","journal-title":"Oncotarget"},{"issue":"5","key":"402_CR81","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/leu.2012.329","volume":"27","author":"DE Spaner","year":"2013","unstructured":"Spaner DE, Lee E, Shi Y, Wen F, Li Y, Tung S, McCaw L, Wong K, Gary-Gouy H, Dalloul A, Ceddia R, Gorzcynski R. PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia. 2013;27(5):1090\u20139. https:\/\/doi.org\/10.1038\/leu.2012.329.","journal-title":"Leukemia"},{"issue":"2","key":"402_CR82","first-page":"428","volume":"12","author":"L Chen","year":"2020","unstructured":"Chen L, Peng J, Wang Y, Jiang H, Wang W, Dai J, Tang M, Wei Y, Kuang H, Xu G, Xu H, Zhou F. Fenofibrate-induced mitochondrial dysfunction and metabolic reprogramming reversal: the anti-tumor effects in gastric carcinoma cells mediated by the PPAR pathway. Am J Transl Res. 2020;12(2):428\u201346.","journal-title":"Am J Transl Res"},{"issue":"3","key":"402_CR83","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.gastro.2019.05.057","volume":"157","author":"Y Luo","year":"2019","unstructured":"Luo Y, Xie C, Brocker CN, Fan J, Wu X, Feng L, Wang Q, Zhao J, Lu D, Tandon M, Cam M, Krausz KW, Liu W, Gonzalez FJ. Intestinal PPAR\u03b1 protects against colon carcinogenesis via regulation of methyltransferases DNMT1 and PRMT6. Gastroenterology. 2019;157(3):744-759.e4. https:\/\/doi.org\/10.1053\/j.gastro.2019.05.057.","journal-title":"Gastroenterology"},{"issue":"7","key":"402_CR84","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/onc.2017.401","volume":"37","author":"J Xue","year":"2018","unstructured":"Xue J, Zhu W, Song J, Jiao Y, Luo J, Yu C, Zhou J, Wu J, Chen M, Ding WQ, Cao J, Zhang S. Activation of PPAR\u03b1 by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt\/\u03b2-catenin pathway. Oncogene. 2018;37(7):953\u201362. https:\/\/doi.org\/10.1038\/onc.2017.401.","journal-title":"Oncogene"},{"key":"402_CR85","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.3748\/wjg.v20.i26.8681","volume":"20","author":"H Chen","year":"2014","unstructured":"Chen H, Shen ZY, Xu W, Fan TY, Li J, Lu YF, et al. Expression of P450 and nuclear receptors in normal and end-stage Chinese livers. World J Gastroenterol. 2014;20:8681\u201390. https:\/\/doi.org\/10.3748\/wjg.v20.i26.8681.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"402_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101228","volume":"7","author":"B Pan","year":"2024","unstructured":"Pan B, Zhang Z, Ye D, Zhang X, Yao Y, Luo Y, Hong H, Cai X, Chen Y, Tang N. PPAR\u03b1 suppresses growth of hepatocellular carcinoma in a high-fat diet context by reducing neutrophil extracellular trap release. JHEP Rep. 2024;7(1): 101228. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101228.","journal-title":"JHEP Rep"},{"issue":"1","key":"402_CR87","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1042\/BJ20050964","volume":"395","author":"R Grau","year":"2006","unstructured":"Grau R, Punz\u00f3n C, Fresno M, I\u00f1iguez MA. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochem J. 2006;395(1):81\u20138. https:\/\/doi.org\/10.1042\/BJ20050964.","journal-title":"Biochem J"},{"issue":"13","key":"402_CR88","doi-asserted-by":"publisher","first-page":"15577","DOI":"10.18632\/oncotarget.6402","volume":"7","author":"K Chandran","year":"2016","unstructured":"Chandran K, Goswami S, Sharma-Walia N. Implications of a peroxisome proliferator-activated receptor alpha (PPAR\u03b1) ligand clofibrate in breast cancer. Oncotarget. 2016;7(13):15577\u201399. https:\/\/doi.org\/10.18632\/oncotarget.6402.","journal-title":"Oncotarget"},{"issue":"1","key":"402_CR89","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2119\/molmed.2015.00139","volume":"21","author":"D Messmer","year":"2015","unstructured":"Messmer D, Lorrain K, Stebbins K, Bravo Y, Stock N, Cabrera G, Correa L, Chen A, Jacintho J, Chiorazzi N, Yan XJ, Spaner D, Prasit P, Lorrain D. A selective novel peroxisome proliferator-activated receptor (PPAR)-\u03b1 antagonist induces apoptosis and inhibits proliferation of CLL cells in vitro and in vivo. Mol Med. 2015;21(1):410\u20139. https:\/\/doi.org\/10.2119\/molmed.2015.00139.","journal-title":"Mol Med"},{"issue":"11","key":"402_CR90","doi-asserted-by":"publisher","first-page":"C890","DOI":"10.1152\/ajpcell.00322.2014","volume":"308","author":"O Abu Aboud","year":"2015","unstructured":"Abu Aboud O, Donohoe D, Bultman S, Fitch M, Riiff T, Hellerstein M, Weiss RH. PPAR\u03b1 inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. Am J Physiol Cell Physiol. 2015;308(11):C890\u20138. https:\/\/doi.org\/10.1152\/ajpcell.00322.2014.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"402_CR91","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3324\/haematol.2023.283864","volume":"109","author":"D Heudobler","year":"2024","unstructured":"Heudobler D, Luke F, Hahn J, Grube M, Schlosser P, Kremers S, Sudhoff T, Westermann J, Hutter-Kronke ML, Schlenk RF, Weber D, Paschka P, Zeman F, Dohner H, Herr W, Reichle A, Thomas S. Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged \u226560 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26\u201316\/AML-ViVA): results of the safety run-in phase. Haematologica. 2024;109(4):1274\u20138. https:\/\/doi.org\/10.3324\/haematol.2023.283864.","journal-title":"Haematologica"},{"issue":"4","key":"402_CR92","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s13277-013-0791-2","volume":"34","author":"Y Liu","year":"2013","unstructured":"Liu Y, Zhu ZA, Zhang SN, Mou J, Liu L, Cui T, Pei DS. Combinational effect of PPAR\u03b3 agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro. Tumour Biol. 2013;34(4):2409\u201318. https:\/\/doi.org\/10.1007\/s13277-013-0791-2.","journal-title":"Tumour Biol"},{"issue":"2","key":"402_CR93","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/a:1016114026769","volume":"74","author":"E Elstner","year":"2002","unstructured":"Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, Possinger K, Koeffler HP. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat. 2002;74(2):155\u201365. https:\/\/doi.org\/10.1023\/a:1016114026769.","journal-title":"Breast Cancer Res Treat"},{"issue":"35","key":"402_CR94","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1038\/sj.onc.1206824","volume":"22","author":"M Pignatelli","year":"2003","unstructured":"Pignatelli M, Cocca C, Santos A, Perez-Castillo A. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene. 2003;22(35):5446\u201350. https:\/\/doi.org\/10.1038\/sj.onc.1206824.","journal-title":"Oncogene"},{"issue":"22","key":"402_CR95","doi-asserted-by":"publisher","first-page":"20087","DOI":"10.1074\/jbc.M110.191718","volume":"286","author":"BH Park","year":"2011","unstructured":"Park BH, Lee SB, Stolz DB, Lee YJ, Lee BC. Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells. J Biol Chem. 2011;286(22):20087\u201399. https:\/\/doi.org\/10.1074\/jbc.M110.191718.","journal-title":"J Biol Chem"},{"issue":"5","key":"402_CR96","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00432-010-0952-2.-89","volume":"137","author":"K Br\u00e4utigam","year":"2011","unstructured":"Br\u00e4utigam K, Biernath-W\u00fcpping J, Bauerschlag DO, von Kaisenberg CS, Jonat W, Maass N, Arnold N, Meinhold-Heerlein I. Combined treatment with TRAIL and PPAR\u03b3 ligands overcomes chemoresistance of ovarian cancer cell lines. J Cancer Res Clin Oncol. 2011;137(5):875\u201386. https:\/\/doi.org\/10.1007\/s00432-010-0952-2.-89.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"64","key":"402_CR97","doi-asserted-by":"publisher","first-page":"107744","DOI":"10.18632\/oncotarget.22632","volume":"8","author":"ML Plissonnier","year":"2017","unstructured":"Plissonnier ML, Fauconnet S, Bittard H, Mougin C, Rommelaere J, Lascombe I. Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells. Oncotarget. 2017;8(64):107744\u201362. https:\/\/doi.org\/10.18632\/oncotarget.22632.","journal-title":"Oncotarget"},{"issue":"2","key":"402_CR98","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.canlet.2008.10.023","volume":"275","author":"WH Sun","year":"2009","unstructured":"Sun WH, Chen GS, Ou XL, Yang Y, Luo C, Zhang Y, Shao Y, Xu HC, Xiao B, Xue YP, Zhou SM, Zhao QS, Ding GX. Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett. 2009;275(2):247\u201355. https:\/\/doi.org\/10.1016\/j.canlet.2008.10.023.","journal-title":"Cancer Lett"},{"key":"402_CR99","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/sj.bjc.6603343","volume":"95","author":"O Takayama","year":"2006","unstructured":"Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, Tsujino T, Takemasa I, Ikeda M, Sekimoto M, et al. Expression of PPAR[delta] in multistage carcinogenesis of the colorectum: Implications of malignant cancer morphology. Br J Cancer. 2006;95:889\u201395. https:\/\/doi.org\/10.1038\/sj.bjc.6603343.","journal-title":"Br J Cancer"},{"key":"402_CR100","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1007\/s10620-010-1389-9","volume":"56","author":"M Yoshinaga","year":"2011","unstructured":"Yoshinaga M, Taki K, Somada S, Sakiyama Y, Kubo N, Kaku T, Tsuruta S, Kusumoto T, Sakai H, Nakamura K, et al. The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients. Dig Dis Sci. 2011;56:1194\u2013200. https:\/\/doi.org\/10.1007\/s10620-010-1389-9.","journal-title":"Dig Dis Sci"},{"key":"402_CR101","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.91419","volume":"2","author":"X Zuo","year":"2017","unstructured":"Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, et al. Metastasis regulation by PPARD expression in cancer cells. JCI Insight. 2017;2: e91419. https:\/\/doi.org\/10.1172\/jci.insight.91419.","journal-title":"JCI Insight"},{"issue":"1","key":"402_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcp.20998","volume":"212","author":"P Sertznig","year":"2007","unstructured":"Sertznig P, Seifert M, Tilgen W, Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol. 2007;212(1):1\u201312. https:\/\/doi.org\/10.1002\/jcp.20998.","journal-title":"J Cell Physiol"},{"issue":"1","key":"402_CR103","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrc1254","volume":"4","author":"L Michalik","year":"2004","unstructured":"Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004;4(1):61\u201370. https:\/\/doi.org\/10.1038\/nrc1254.","journal-title":"Nat Rev Cancer"},{"key":"402_CR104","doi-asserted-by":"publisher","first-page":"12890","DOI":"10.1073\/pnas.0705505104","volume":"104","author":"A Abdollahi","year":"2007","unstructured":"Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P, Hauser K, Hahnfeldt P, Hlatky L, Debus J, et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA. 2007;104:12890\u20135. https:\/\/doi.org\/10.1073\/pnas.0705505104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"402_CR105","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1165\/rcmb.2007-0426OC","volume":"39","author":"TV Pedchenko","year":"2008","unstructured":"Pedchenko TV, Gonzalez AL, Wang D, DuBois RN, Massion PP. Peroxisome proliferator-activated receptor beta\/delta expression and activation in lung cancer. Am J Respir Cell Mol Boil. 2008;39:689\u201396. https:\/\/doi.org\/10.1165\/rcmb.2007-0426OC.","journal-title":"Am J Respir Cell Mol Boil"},{"key":"402_CR106","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.biochi.2016.10.019","volume":"136","author":"R M\u00fcller","year":"2017","unstructured":"M\u00fcller R. PPAR\u03b2\/\u03b4 in human cancer. Biochimie. 2017;136:90\u20139. https:\/\/doi.org\/10.1016\/j.biochi.2016.10.019.","journal-title":"Biochimie"},{"issue":"5","key":"402_CR107","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1073\/pnas.051630998","volume":"98","author":"BH Park","year":"2001","unstructured":"Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A. 2001;98(5):2598\u2013603. https:\/\/doi.org\/10.1073\/pnas.051630998.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"402_CR108","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1158\/0008-5472.CAN-05-4277","volume":"66","author":"HE Marin","year":"2006","unstructured":"Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res. 2006;66(8):4394\u2013401. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4277.","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"402_CR109","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.tox.2007.10.023","volume":"243","author":"EE Girroir","year":"2008","unstructured":"Girroir EE, Hollingshead HE, Billin AN, Willson TM, Robertson GP, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-beta\/delta (PPARbeta\/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology. 2008;243(1\u20132):236\u201343. https:\/\/doi.org\/10.1016\/j.tox.2007.10.023.","journal-title":"Toxicology"},{"issue":"7","key":"402_CR110","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/carcin\/bgx035","volume":"38","author":"W Zhang","year":"2017","unstructured":"Zhang W, Xu Y, Xu Q, Shi H, Shi J, Hou Y. PPAR\u03b4 promotes tumor progression via activation of Glut1 and SLC1-A5 transcription. Carcinogenesis. 2017;38(7):748\u201355. https:\/\/doi.org\/10.1093\/carcin\/bgx035.","journal-title":"Carcinogenesis"},{"key":"402_CR111","doi-asserted-by":"publisher","first-page":"176565","DOI":"10.1016\/j.ejphar.2024.176565","volume":"972","author":"B Khan","year":"2024","unstructured":"Khan B, Chen M, Wang H, Khan A, Hussain S, Shi J, Yang L, Hou Y. GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression. Eur J Pharmacol. 2024;972:176565. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176565. Epub 2024 Apr 9. PMID: 38599309.","journal-title":"Eur J Pharmacol"},{"issue":"13","key":"402_CR112","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.4161\/cbt.8.13.8691","volume":"8","author":"NT Zaveri","year":"2009","unstructured":"Zaveri NT, Sato BG, Jiang F, Calaoagan J, Laderoute KR, Murphy BJ. A novel peroxisome proliferator-activated receptor delta antagonist, SR13904, has anti-proliferative activity in human cancer cells. Cancer Biol Ther. 2009;8(13):1252\u201361. https:\/\/doi.org\/10.4161\/cbt.8.13.8691.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"402_CR113","doi-asserted-by":"publisher","first-page":"95","DOI":"10.31083\/j.fbl2703095","volume":"27","author":"Hongdan Chen","year":"2022","unstructured":"Chen Hongdan, Yang Zeyu, Sun Yiceng, Yin Supeng, Tang Mi, Zhang Fan. Targeting the key enzymes of abnormal fatty acid \u03b2-oxidation as a potential strategy for tumor therapy. Front Biosci (Landmark Ed). 2022;27(3):95. https:\/\/doi.org\/10.31083\/j.fbl2703095.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"402_CR114","doi-asserted-by":"publisher","unstructured":"Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE, Schafer ZT, Evans RM, Suda T, Lee CH, Pandolfi PP. A PML\u2013PPAR-\u03b4 pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med. 2012;18(9):1350\u20138. https:\/\/doi.org\/10.1038\/nm.2882.","DOI":"10.1038\/nm.2882"}],"container-title":["Cancer &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40170-025-00402-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:06:18Z","timestamp":1757289978000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerandmetabolism.biomedcentral.com\/articles\/10.1186\/s40170-025-00402-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1186\/s40170-025-00402-5","relation":{},"ISSN":["2049-3002"],"issn-type":[{"value":"2049-3002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}